1 / 40

Diabetic Retinopathy

Diabetic Retinopathy. Steven Sanislo, M.D. Assistant Professor Stanford University Department of Ophthalmology. Diabetic Retinopathy. Diabetic retinopathy is a leading cause of new cases of blindness in people aged 20 to 74 years in the USA

powa
Download Presentation

Diabetic Retinopathy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diabetic Retinopathy Steven Sanislo, M.D. Assistant Professor Stanford University Department of Ophthalmology

  2. Diabetic Retinopathy • Diabetic retinopathy is a leading cause of new cases of blindness in people aged 20 to 74 years in the USA • Many of the complications of diabetic retinopathy can be prevented or delayed by blood glucose control and timely intervention.

  3. Ocular Anatomy

  4. Retinal Anatomy

  5. Retinal Histology Sclera Choroid RPE Photoreceptor outer segments Photoreceptor inner segment Outer Plexiform layer Bipolar cells Inner plexiform layer Ganglion cells Nerve fiber layer

  6. Retinal Diagnostic Tests • Fundus Photography • Fluorescein Angiography (FA) • Optical Coherence Tomography (OCT) • Ocular Ultrasonography • Electroretinography (ERG)

  7. Fundus Photos and FA

  8. Fundus Photography

  9. Normal FA

  10. Optical Coherence Tomography (OCT)

  11. Normal OCT

  12. B-scan Ultrasound

  13. Normal Ultrasound

  14. Pathogenesis of DR • Prolonged hyperglycemia is the major etiologic agent in all of the microvascular complications of diabetes, including diabetic retinopathy. • The cellular mechanisms through which hyperglycemia acts currently remain unclear

  15. Pathogenesis of DR Mechanisms that have been proposed are: • 1. hyperglycemia may alter the expression of one or more genes, leading to increased (or decreased) amounts of certain gene products that can alter cellular functions. • 2. Glycosylated proteins can undergo a series of reactions, leading to considerable alteration of proteins. • 3. Chronic hyperglycemia may produce oxidative stress in cells, leading to the formation of an excess of "toxic end products of oxidation" including peroxides, superoxides, nitric oxide, and oxygen free radicals.

  16. VEGF and DR • Vascular Endothelial Growth Factor • Promotes vascular growth and permeability • Elevated levels of circulating VEGF in conditions with retinal ischemia

  17. Anatomic Changes Microanerysms • Damage to endothelial cells leads to dilated capillaries and venules • These altered vessels allow serum and blood to leak into the retina

  18. NPDR

  19. NPDR FA

  20. NPDR OCT

  21. Retinal Ischemia

  22. PDR

  23. PDR

  24. PDR FA

  25. Vitreous Hemorrhage (VH)

  26. VH ultrasound

  27. TRD ultrasound

  28. Epiretinal Membrane

  29. PDR Retinal Detachment

  30. Iris Neovascularization

  31. Mechanisms of Vision Loss • Retinal ischemia • Macular edema • Vitreous hemorrhage • Epiretinal membrane formation • Retinal detachment • Neovascular glaucoma

  32. Prevention • Prospective controlled interventional studies have shown that strict control of blood glucose and blood pressure significantly reduces and delays the onset and severity of diabetic retinopathy.

  33. Screening Type 1 diabetics: First screen 5 years after onset, then annually. Type 2 diabetics: First screen upon diagnosis and then annually.

  34. Treatment • NPDR without macular edema - • Observe • Macular edema - • 1. Focal/Grid laser photocoagulation • 2. Vitrectomy with membrane peeling • 3. Intraocular Steroid* • 4. Intraocular VEGF inhibitor* * Off-label use, contraversial

  35. DME laser treatment

  36. DME laser treatment * * * * * * * * * * * *

  37. Treatment • Vitreous Hemorrhage - • 1. Pan-retinal photocoagulation • 2. Vitrectomy with laser photocoagulation • 3. Intraocular VEGF inhibitor* • Traction Retinal Detachment - • 1. Observation if not involving the macula • 2. Vitrectomy with membrane dissection * Off-label use, contraversial

  38. Pan-retinal Photocoagulation

  39. Vitrectomy

  40. http://www.youtube.com/watch?v=iOwpEa4KB5c

More Related